Afrezza® INHALE-1 Study in Pediatrics
Trial details
- Registry ID
- NCT04974528
- Phase
- Phase 3
The FDA approved Afrezza (Technosphere Insulin) on 27 Jun 2014.
Drug identity checked against registry records
Also recorded as Technosphere Insulin
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Afrezza® INHALE-1 Study in PediatricsNCT04974528 | Mannkind Corporation | Phase 3 | Completed | 2024-10-03Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2014-06-27Day | Afrezza | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA022472", "applicant_as_listed_by_fda": "MANNKIND", "brand_names": ["AFREZZA"], "active_ingredients": ["INSULIN RECOMBINANT HUMAN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20140627", "matched_on": "drug name equals FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |